

30th
& 31st
OCTOBER
2025

14th ANNUAL ACUTE LEUKEMIA MEETING

IN PERSON & VIRTUAL EVENT

DIRECTOR

Dr. Adolfo de la Fuente
MD Anderson Cancer Center Madrid-Hospiten, Spain

www.MDAndersonHospiten.es/CursoLeucemia



Scientific Committee

Dr. María José Calasanz

Clinica Universidad de Navarra, Pamplona, Spain

Dr. Valentín García-Gutiérrez

Hospital Universitario Ramón y Cajal, Madrid, Spain

Dr. Guillermo García-Manero

MD Anderson Cancer Center, Houston, USA

Dr. Mayte Olave

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Dr. Mar Tormo

Hospital Clínico Universitario de Valencia, Spain

Dr. David Valcárcel

Hospital Universitario Vall d'Hebron, Institute of Oncology, Barcelona, Spain

Dr. Claudio Cerchione

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy

Dr. Alessandro Isidori

Marche Nord Hospital, Pesaro, Italy

Dr. Elias Jabbour

MD Anderson Cancer Center, Houston, USA

Dr. Gabriela Rodríguez Macías

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Dr. Ana Alarcón Tomás

Hospital Universitario Puerta de Hierro, Madrid, Spain



Ambassadors

Dr. María Marta Rivas

Hospital Universitario Austral, Buenos Aires, Argentina

Dr. Virginia Abello Polo

Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center, Bogotá, Colombia

Dr. Mónica Alejandra Romero Riquelme

Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile

Dr. Carlos Plaza

UEES Clinic y SOLCA Guayaquil, Ecuador

Dr. Breno Moreno de Gusmão

Benecência Portuguesa de São Paulo, São Paulo, Brasil

Dr. Sofía Grille

Hospital de Clínicas Dr. Manuel Quintela, Montevideo, Uruguay

Dr. Gilberto Barranco

Hospital General de México, Mexico City, Mexico

Dr. Mika Kontro

Helsinki University Hospital Comprehensive Cancer Center, Finland

Dr. Anne Louise Tølbøll Sørensen

Copenhagen University Hospital - Rigshospitalet, Denmark

Dr. Margarida Coucelo

Unidade Local de Saúde de Coimbra, Portugal

Dr. Luís Pedro Monteiro

Unidade Local de Saúde São José, Lisboa, Portugal

Dr. Claudia Núñez-Torrón Stock

Hospital Universitario Infanta Sofía, Madrid, Spain

Thursday

30th october 2025

09:30 - 09:40

Introduction and Welcome

Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid-Hospiten, Spain

09:40 - 11:00

SESSION 1

Myelofibrosis

Chairs:

Dr. Valentín García-Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain
Dr. Breno Moreno de Gusmão, Benecência Portuguesa de São Paulo, São Paulo, Brasil
Dr. Gilberto Barranco, Hospital General de México, Mexico City, Mexico

09:40 - 10:00

New response criteria

Dr. Valentín García-Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain

10:00 - 10:20

Symptomatic and anemic myelofibrosis: can we treat everything with a single agent?

Dr. Santiago Osorio, Hospital General Universitario Gregorio Marañón, Madrid, Spain

10:20 - 10:40

When and Who Should Get a Transplant?

Dr. Anabelle Chinae, Hospital Universitario Ramón y Cajal, Madrid, Spain

10:40 - 11:00

Discussion

11:00 - 11:30

Coffee break

11:30 - 12:50

SESSION 2

IDH1 meet the experts

Chairs:

Dr. Claudia Núñez-Torrón Stock, Hospital Universitario Infanta Sofía, Madrid, Spain
Dr. Mika Kontro, Helsinki University Hospital Comprehensive Cancer Center, Finland
Dr. Anne Louise Tølbøll Sørensen, Copenhagen University Hospital - Rigshospitalet, Denmark

11:30 - 11:50

Molecular and Genetic Profiling: Transforming Risk Stratification into Targeted Therapy

Dr. Margarida Coucelo, Unidade Local de Saúde de Coimbra, Portugal

11:50 - 12:10

Balancing Promise and Peril: Adverse Events in AML Targeted Treatment

Dr. Susana Vives Polo, Hospital Germans Trias i Pujol, Barcelona, Spain

12:10 - 12:30

Agile trial

Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid-Hospiten, Spain

12:30 - 12:50

Discussion with the experts:

Dr. Gail Roboz, New York Presbyterian Hospital, USA
Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany

12:50 - 14:10

SESSION 3**MDS 1**

Chairs: Dr. David Valcárcel, *Hospital Universitario Vall d'Hebron, Institute of Oncology, Barcelona, Spain*
Dr. Gilberto Barranco, *Hospital General de México, Mexico City, Mexico*
Dr. Luís Pedro Monteiro, *Unidade Local de Saúde São José, Lisboa, Portugal*

12:50 - 13:10

CHIP/CCUS: Is it time to intervene?

Dr. Julia Montoro, *Hospital Universitario Vall d'Hebron, Barcelona, Spain*

13:10 - 13:30

Re-thinking low risk MDS

Dr. María Díez Campelo, *Hospital Universitario de Salamanca, Spain*

13:30 - 13:50

The challenge of High Risk MDS

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

13:50 - 14:10

Discussion

14:10 - 15:30

Lunch

14:45 - 15:30

LUNCH SESSION**L-Annamycin - Non-Cardiotoxic Anthracycline; MIRACLE Pivotal AML Study**

Dr. Paul Waymack, *CMO at Moleculin*

Sponsored by: Moleculin

15:30 - 17:10

SESSION 4**Diagnosis and MRD**

Chairs: Dr. María José Calasanz, *Clínica Universidad de Navarra, Pamplona, Spain*
Dr. Margarida Coucelo, *Unidade Local de Saúde de Coimbra, Portugal*
Dr. Alessandro Isidori, *Ospedale Marche Nord, Pesaro, Italy*

15:30 - 15:50

Genetic characterization in myeloid neoplasms at diagnosis

Dr. María José Calasanz, *Clínica Universidad de Navarra, Pamplona, Spain*

15:50 - 16:10

Value of cytometry for MRD monitoring in AML

Dr. Sylvie Freeman, *University of Birmingham, UK*

16:10 - 16:30

MRD monitoring in Acute Myeloid Leukemia: The Key Role of Molecular Genomics

Dr. Eva Barragán, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

16:30 - 16:50

MRD predictive value in ALL: multiparametric flow cytometry in clinical practice

Dr. Alberto Orfao, *Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC), España*

16:50 - 17:10

Discussion

17:10 - 17:30

Coffee break

17:30 - 18:30

SESSION 5

ALL

Chairs:

Dr. Carlos Plaza, *UEES Clinic and SOLCA Guayaquil, Ecuador*
 Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*
 Dr. Ana Alarcón Tomas, *Hospital Universitario Puerta de Hierro, Madrid, Spain*

17:30 - 17:50

Blinatumomab finally a reality

Dr. Anna Torrent, *Hospital Universitario Germans Trias i Pujol, Barcelona, Spain*

17:50 - 18:10

And after what? immunotherapy in R/R ALL (excluding CAR-T)

Dr. Cristina Papayannidis, *IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy*

18:10 - 18:30

Discussion

18:30 - 19:50

SESSION 6

The long road to a new treatment

Chairs:

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*
 Dr. Luís Pedro Monteiro, *Unidade Local de Saúde São José, Lisboa, Portugal*
 Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

18:30 - 18:50

Between lines and leukemias: Deciphering Trials

Dr. Regina Garcia, *Hospital Universitario Virgen de la Victoria, Málaga, Spain*

18:50 - 19:10

EMA regulation of new drugs

Dr. Ricardo Cubedo, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

19:10 - 19:30

New Molecules in Development for AML

Dr. Hartmut Döhner, *Universitätsklinikum Ulm, Germany*

19:30 - 19:50

Discussion

09:00 - 10:40

SESSION 7**Immunotherapy***Chairs:*Dr. Ana Alarcón Tomas, *Hospital Universitario Puerta de Hierro, Madrid, Spain*Dr. Margarida Coucelo, *Unidade Local de Saúde de Coimbra, Portugal*Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

09:00 - 09:20

Immunopeptidome analysis in AMLDr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*

09:20 - 09:40

CAR-T therapy beyond CD19Dr. Felipe Prósper, *Clínica Universidad de Navarra, Pamplona, Spain*

09:40 - 10:00

A novel macrophage activator, bexmarilimab, results on AML and MDSDr. Mika Kontro, *Helsinki University Hospital Comprehensive Cancer Center, Finland*

10:00 - 10:20

Bi-specific antibodies for AMLDr. Ana Alfonso Pierola, *Clínica Universidad de Navarra, Pamplona, Spain*

10:20 - 10:40

Discussion

10:40 - 11:00

Coffee break

11:00 - 12:20

SESSION 8**Fit and Unfit in AML: A matter Beyond Age***Chairs:*Dr. Gabriela Rodríguez Macías, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*Dr. Anne Louise Tølbøll Sørensen, *Copenhagen University Hospital - Rigshospitalet, Denmark*Dr. Carlos Plaza, *UEES Clinic y SOLCA Guayaquil, Ecuador*

11:00 - 11:20

Multidisciplinary management, the role of the geriatricianDr. Maite Vidán, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*

11:20 - 11:40

Intensive strategies in high-risk AML: beyond 7+3Dr. Alessandro Isidori, *Ospedale Marche Nord, Pesaro, Italy*

11:40 - 12:00

How to treat patients aged 80 and aboveDr. Yakir Moshe, *Tel Aviv Sourasky Medical Center, Israel*

12:00 - 12:20

Discussion

Friday

31st october 2025

12:20 - 13:20

SESSION 9

BPDCN

Chairs: Dr. Mayte Olave, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain
Dr. María Marta Rivas, Hospital Universitario Austral, Buenos Aires, Argentina

12:20 - 12:40

BPDCN diagnostic and therapeutic challenge

Dr. María Belén Vidriales, Hospital Clínico Universitario de Salamanca, Spain

12:40 - 13:00

BPDCN management and real-life data

Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy

13:00 - 13:20

Discussion

13:20 - 14:25

SESSION 10

Re-thinking AML management

Chairs: Dr. David Valcárcel, Hospital Universitario Vall d'Hebron, Institute of Oncology, Barcelona, Spain
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid-Hospiten, Spain
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy

13:20 - 13:40

Low-intensity treatment in AML, focusing on monotherapy vs. combinations vs. sequencing

Dr. Gail Roboz, New York Presbyterian Hospital, USA

13:40 - 14:00

Rethinking the Role of Intensive Chemotherapy for Fit Patients

Dr. Alexander Perl, Abramson Cancer Center, Pennsylvania, USA

14:00 - 14:25

Discussion

14:25 - 15:30

Lunch

15:30 - 16:10

SESSION 11**Meet the Expert Management of FLT3 mut AML in 1st line***Chairs:*

Dr. María Marta Rivas, *Hospital Universitario Austral, Buenos Aires, Argentina*
Dr. Claudia Núñez-Torrón Stock, *Hospital Universitario Infanta Sofía, Madrid, Spain*
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

15:30 - 15:50

FLT3 inhibitors in frontline, the big picture

Dr. Luís Pedro Monteiro, *Unidade Local de Saúde São José, Lisboa, Portugal*

15:50 - 16:10

Experts:

Dr. Alexander Perl, *Abramson Cancer Center, Pennsylvania, USA*
Dr. Hartmut Döhner, *Universitätsklinikum Ulm, Germany*

16:10 - 17:30

SESSION 12**My day-to-day life at the AML***Chairs:*

Dr. Mónica Alejandra Romero Riquelme, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile*
Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*
Dr. Gilberto Barranco, *Hospital General de México, Mexico City, Mexico*

16:10 - 16:30

Maintenance in AML to whom and with what between opportunities and restrictions.

Dr. Anne Louise Tølbøll Sørensen, *Copenhagen University Hospital - Rigshospitalet, Denmark*

16:30 - 16:50

Treatment of NPM1 mutated AML

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

16:50 - 17:10

Advances in relapsed AML

Dr. Josefina Serrano, *Hospital Universitario Reina Sofía, Córdoba, Spain*

17:10 - 17:30

Discussion

Friday

31st october 2025

17:30-18:50

SESSION 13

Targeted therapies

Chairs:

Dr. Gabriela Rodríguez Macías, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*

Dr. Mika Kontro, *Helsinki University Hospital Comprehensive Cancer Center, Finland*

Dr. Mónica Alejandra Romero Riquelme, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile*

17:30 - 17:50

Menin inhibitors in AML

Dr. Cristina Papayannidis, *IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy*

17:50 - 18:10

Targeting KIT in systemic mastocytosis

Dr. Iván Álvarez-Twose, *Complejo Hospitalario Universitario de Toledo, Spain*

18:10 - 18:30

Targeting KMT2A in ALL

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

18:30 - 18:50

Discussion

18:50 - 19:00

Closing and farewell

Sponsors

PLATINUM

abbvie

SERVIER
moved by you

GOLD

 **astellas**

 **MENARINI**
group

Stemline
A Menarini Group Company

SILVER

AstraZeneca 

 **Bristol Myers Squibb**[™]

GSK

Incyte

 **Otsuka**

Syndax 

BRONZE

 **Jazz Pharmaceuticals**

 **MOLECULIN**

 **Pfizer**

COLLABORATORS

 **blueprint**
MEDICINES
a sanofi company

Organized By

**MD Anderson
Cancer Center**
Fundación • España

**MD Anderson
Cancer Center**
Madrid • España



Accreditation

Credits requested from the Continuing Education Commission
of Health Professions of the Community of Madrid

Auspice

With the scientific endorsement of



Sociedad Española de
Hematología y Hemoterapia

Venue

MD Anderson Cancer Center Spain Foundation Auditorium
C/ Arturo Soria, 270, 28033, Madrid



Technical Secretariat

Tel.: (+34) 91 372 02 03

e-mail: cursoleucemia@doctaforum.com

www.MDAndersonHospiten.es/CursoLeucemia